Providing a VOICE for Iowa's MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 1992
Meetings & Education
IOS Allied Health Professional Award
Financial Advocacy & Patient Assistance
IOS Advocacy Support
Patient Advocacy Organizations
IOS Quality Award Program
IOS Quality Award Application
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
IOS Corporate Members
Become a Supporter
Industry News Archive
FDA Restricts Use of Keytruda and Tecentriq for Urothelial Cancer
On June 20, 2018, the FDA announced that it was restricting the use of Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
This restriction results from decreased survival associated with the use of Keytruda or Tecentriq as monotherapy compared to platinum-based chemotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
Read the full FDA announcement here.
Tweets by OSSatACCC